Evidence map›Paper›PMID 38004384›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Benzimidazoles Containing Piperazine Skeleton at C-2 Position as Promising Tubulin Modulators with Anthelmintic and Antineoplastic Activity.

Kameliya Anichina, Anelia Mavrova, Dimitar Vuchev, Galya Popova-Daskalova, Giada Bassi, Arianna Rossi, Monica Montesi, Silvia Panseri, Filip Fratev, Emilia Naydenova

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review of promising benzimidazole-based anticancer agents (2023-2026).Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kameliya AnichinaDepartment of Organic Synthesis, University of Chemical Technology and Metallurgy, 8 Kliment Ohridski Blvd., 1756 Sofia, Bulgaria.ORCID 0000-0001-5236-0567
Anelia MavrovaDepartment of Organic Synthesis, University of Chemical Technology and Metallurgy, 8 Kliment Ohridski Blvd., 1756 Sofia, Bulgaria.ORCID 0000-0002-0455-4321
Dimitar VuchevDepartment of Infectious Diseases, Parasitology and Tropical Medicine, Medical University, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.
Galya Popova-DaskalovaDepartment of Infectious Diseases, Parasitology and Tropical Medicine, Medical University, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.
Giada BassiInstitute of Science, Technology and Sustainability for Ceramics, National Research Council of Italy, Via Granarolo 64, 48018 Faenza, Italy.
Arianna RossiInstitute of Science, Technology and Sustainability for Ceramics, National Research Council of Italy, Via Granarolo 64, 48018 Faenza, Italy.ORCID 0000-0001-9863-7701
Monica MontesiInstitute of Science, Technology and Sustainability for Ceramics, National Research Council of Italy, Via Granarolo 64, 48018 Faenza, Italy.ORCID 0000-0002-9192-8554
Silvia PanseriInstitute of Science, Technology and Sustainability for Ceramics, National Research Council of Italy, Via Granarolo 64, 48018 Faenza, Italy.ORCID 0000-0002-8099-7132
Filip FratevMicar Innovation (Micar 21) Ltd., 34B Persenk Str., 1407 Sofia, Bulgaria.ORCID 0000-0002-9651-9442
Emilia NaydenovaDepartment of Organic Chemistry, University of Chemical Technology and Metallurgy, 8 Kliment Ohridski Blvd., 1756 Sofia, Bulgaria.ORCID 0000-0002-2999-5094

Funding

Ministry of Education and Science (Republic Bulgaria), National Program" EUROPEAN SCIENTIFIC NETWORKS", project "Drug molecule" D01-278/05.10.2020
6 · The paper itself

Abstract

Benzimidazole anthelmintic drugs hold promise for repurposing as cancer treatments due to their interference with tubulin polymerization and depolymerization, manifesting anticancer properties. We explored the potential of benzimidazole compounds with a piperazine fragment at C-2 as tubulin-targeting agents. In particular, we assessed their anthelmintic activity against isolated

Indexed as

absolute free energy of perturbation (ABFEP)anthelmintic activityantitumor activitybenzimidazolecell migrationIFD-MDinduced fit dockingLDH cellular releasemolecular dynamics simulationpiperazinetubulin modulators

Identifiers

PMID38004384
PMCPMC10675210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.